Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Russell F. Palm

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0448-8715; OpenAlex author ID A5018847418. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2021: 1 paper · 2022: 1 paper · 2023: 4 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 8

  1. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  2. Personalizing Patient Education for Pancreatic Cancer Patients Receiving Multidisciplinary Care with Integration of Novel Digital Tools. Co-author DOI 10.3390/healthcare13151929↗
  3. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic R… First author DOI 10.1177/10732748221150228↗
  4. Ablative 5-Fraction Stereotactic MRI-Guided Adaptive Radiotherapy for Oligometastatic Pancreatic Adenocarcinoma. Last author DOI 10.1177/10732748231219069↗
  5. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analy… Co-author DOI 10.1245/s10434-023-13353-2↗
  6. ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer-Resection Cuts the Deal. Co-author DOI 10.1245/s10434-023-13484-6↗
  7. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation … First author DOI 10.1016/j.adro.2022.101045↗
  8. Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. Co-author DOI 10.1186/s13014-021-01957-5↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sarah E. Hoffe · 7 shared papers, 2021–2026 · strength 1.10
  2. Jessica M. Frakes · 5 shared papers, 2021–2025 · strength 0.79
  3. Dilmurodjon Eshmuminov · 3 shared papers, 2023–2026 · strength 0.57
  4. Kuno Lehmann · 2 shared papers, 2023 · strength 0.38
  5. Pamela Joy Hodul · 2 shared papers, 2023–2025 · strength 0.36
  6. Michael David Chuong · 2 shared papers, 2023 · strength 0.31
  7. Giuseppe Malleo · 2 shared papers, 2023–2026 · strength 0.31
  8. Gregory C. Wilson · 2 shared papers, 2023–2026 · strength 0.31
  9. Ryan K. Schmocker · 2 shared papers, 2023–2026 · strength 0.31
  10. Jin Peng He · 2 shared papers, 2023–2026 · strength 0.31
  11. Víctor López‐López · 2 shared papers, 2023–2026 · strength 0.31
  12. Elena B. Rangelova · 2 shared papers, 2023–2026 · strength 0.31
  13. Sameer H. Patel · 2 shared papers, 2023–2026 · strength 0.31
  14. Changhoon Yoo · 2 shared papers, 2023–2026 · strength 0.31
  15. John Michael Bryant · 2 shared papers, 2022–2023 · strength 0.29
  16. Jason W. Denbo · 2 shared papers, 2022–2023 · strength 0.29
  17. Mokenge Peter Malafa · 2 shared papers, 2022–2023 · strength 0.29
  18. Jason B. Fleming · 2 shared papers, 2022–2023 · strength 0.29
  19. Joseph M. Herman · 1 shared paper, 2025 · strength 0.21
  20. Nicole Nardella · 1 shared paper, 2025 · strength 0.21
  21. Syed A. Ahmad · 1 shared paper, 2026 · strength 0.19
  22. José Oberholzer · 1 shared paper, 2026 · strength 0.19
  23. Ning Pu · 1 shared paper, 2026 · strength 0.19
  24. Liang Liu · 1 shared paper, 2026 · strength 0.19
  25. Patricia Sánchez‐Velázquez · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.